Bayer and DNDi sign agreement to develop an oral treatment for river blindness

(Drugs for Neglected Diseases Initiative) Bayer HealthCare and the Drugs for Neglected Diseases initiative have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis). The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news